Increase in the ratio of matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 in saliva from patients with primary Sjögren's syndrome

Clinica Chimica Acta

Volumn 345, Issue 1-2, 2004, Pages 99-104

  Asatsuma, Masumi ^a   Ito, Satoshi ^a   Watanabe, Mamoru ^a   Takeishi, Hideyuki ^a   Nomura, Shuichi ^a   Wada, Yoko ^a   Nakano, Masaaki ^b   Gejyo, Fumitake ^a   Igarashi, Atsuko ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

Author keywords

APS; ELISA; enzyme linked immunosorbent assay; matrix metalloproteinase; MMP; MMP 9; Primary Sj gren's syndrome; primary Sj gren's syndrome; pSS; Saliva; SDS; sodium dodecyl sulfate; TIMP; TIMP 1; tissue inhibitor of metalloproteinase

Indexed keywords

GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTROIMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MEASUREMENT; PATIENT; PRIORITY JOURNAL; SALIVA; SALIVA ANALYSIS; SJOEGREN SYNDROME; STIMULATION; ZYMOGRAPHY;

ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PROSPECTIVE STUDIES; SALIVA; SJOGREN'S SYNDROME; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 2942610638     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cccn.2004.03.006     Document Type: Article

References (16)

1. Moutsopoulos H.M., Chused T.M., Mann D.K., et al. Differences in the clinical manifestation of sicca syndrome in the presence and absence of rheumatoid arthritis. Am. J. Med. 66:1979;733-736
2. Konttinen Y.T., Kangaspunta P., Lindy O., et al. Collagenase in Sjögren's syndrome. Ann. Rheum. Dis. 53:1994;836-839
3. Cawston T. Metalloproteinases inhibitors and the prevention of connective tissue breakdown. Pharmacol. Ther. 70:1996;163-182
4. Konttinen Y.T., Halinen S., Hanemaaijer R., et al. Matrix metalloproteinase (MMP)-9 type IV collagenase/gelatinase implicated in the pathogenesis of Sjögren syndrome. Matrix Biol. 17:1998;335-347
5. Hanemaaijer R., Visser H., Konttinen Y.T., et al. A novel and simple immunocapture assay for determination of gelatinase-B (MMP-9) activities in biological fluids: saliva from patients with Sjögren Syndrome contain increased latent and active gelatinase-B levels. Matrix Biol. 17:1998;657-665
6. Gomez D.E., Alonso D.F., Yoshiji H., et al. Tissue inhibitors of metalloproteinases structure, regulation and biological functions. Eur. Cell. Biol. 74:1997;111-122
7. Drouin L., Overall C.M., Sodek J. Identification of matrix metalloproteinases inhibitor (TIMP) in human parotid and submandibular saliva: partial purification and characterization. J. Periodontal. Res. 23:1998;370-377
8. Guedez L., Stetler-Stevenson W.G., Wolff L., et al. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J. Clin. Invest. 102(11):1998;2002-2010
9. Hayakawa T. Multiple functions of tissue inhibitors of metalloproteinases (TIMPs): a new aspect involving osteoclastic bone resorption. J. Bone Miner. Metab. 20:2002;1-13
10. Vitali C., Bombardieri S., Jonsson R., et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann. Rheum. Dis. 61:2002;554-558
11. Hawkes S.P., Li H., Taniguchi G.T. Zymography and reverse zymography for detecting MMPs and TIMPs. Methods Mol. Biol. 151:2001;399-410
12. Oliver G.W., Leferson J.D., Stetler-Stevenson W.G., Kliner D.E. Quantitative reverse zymography: analysis of picogram amounts of metalloproteinase inhibitors using gelatinase A and B reverse zymograms. Anal. Biochem. 244:1997;161-166
13. Overall C.M., Sodek J., McCulloch C.A., et al. Evidence for polymorphonuclear collagenase and 92-kilodalton gelatinase in gingival crevicular fluid. Infect. Immun. 59:1991;4687-4692
14. Wu A.J., Lafrenie R.M., Park C., et al. Modulation of MMP-2 (gelatinase A) and MMP-9 (gelatinase B) by interferon-gamma in a human salivary gland cell line. J. Cell. Physiol. 171:1997;117-124
15. Azuma M., Aota K., Tamatani T., et al. Suppression of tumor necrosis factor alpha-induced matrix matalloproteinase 9 production by the introduction of a super-repressor form of inhibitor of nuclear factor kappaBalpha complementary DNA into immortalized human salivary gland aciner cells. Prevention of the destruction of the aciner structure in Sjögren Syndrome salivary glands. Arthritis Rheum. 43:2000;1756-1767
16. Azuma M., Aota K., Tamatani T., et al. Suppression of tumor necrosis factor alpha-induced matrix matalloproteinase 9 production in human salivary gland aciner cells by cepharantine occurs via down-regulation of nuclear factor kappaB: a possible therapeutic agent for preventing the destruction of the acinar structure in the salivary glands of Sjögren Syndrome patients. Arthritis Rheum. 46:2002;1585-1594